Advertisement

Topics

Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer

2018-02-22 19:05:22 | BioPortfolio

Published on BioPortfolio: 2018-02-22T19:05:22-0500

Clinical Trials [7638 Associated Clinical Trials listed on BioPortfolio]

Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

This phase I trial studies the side effects and best dose of atezolizumab that can be given together with stereotactic body radiation therapy in treating patients with stage I non-small ce...

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus a...

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread to other places in the body, has come back, or d...

A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will evaluate the safety and efficacy of MTIG7192A plus Atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or...

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)

This study is designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with Stage IB, II, or IIIA NSCLC who are eligible for surgical resection...

PubMed Articles [40041 Associated PubMed Articles listed on BioPortfolio]

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we report final analyses from the non-small-cell...

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

Before the availability of immunotherapy, chemotherapy was standard first-line therapy for non-small-cell lung cancer (NSCLC) lacking actionable gene alterations. Preclinical evidence suggests chemoth...

The role of radiation therapy in the management of small cell lung cancer.

Small cell lung cancer (SCLC) is a very aggressive form of lung cancer. SCLC treatment requires multidisciplinary management and timely treatment. Radiation therapy is an important part of management ...

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

Intracranial metastases are a common cause of morbidity and mortality in patients with advanced non-small cell lung cancer (NSCLC), and are frequently managed with radiation therapy (RT). The safety o...

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.

The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced non-small-cell lung cancer (NSCLC) selected by tumor cell (TC)...

Medical and Biotech [MESH] Definitions

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

More From BioPortfolio on "Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial